摘要
目的:观察脂易消对实验性非酒精性脂肪性肝病 (NAFLD) 大鼠肝组织碳水化合物反应元件结合蛋白 (ChREBP)m RNA 表达的影响。方法:采用高脂饮食制备 NAFLD 大鼠模型,分低、中、高剂量脂易消治疗组、易善复胶囊阳性对照组、模型对照组、正常对照组。显微镜下观察 HE 染色后各组肝细胞脂肪变性及肝组织炎性改变情况 ;使用 RT-PCR 法检测各组大鼠肝组织 ChREBP m RNA 的水平。结果:实验结束时模型组体重指数 (BMI) 明显增高,与正常组比较差异有显著统计学意义 ( P <0.01) ;而与模型组相比,脂易消各剂量组及易善复组肝指数明显降低,差异有统计学意义 ( P <0.05) ;但高、中、低剂量组与易善复组比较差异均无统计学意义 ( P >0.05)。光镜观察显示正常对照组没有发生脂肪变性及炎性浸润;模型组总体肝组织脂肪变性程度与正常组肝组织相比有显著的差异。脂易消组肝组织发生弥漫性肝细胞脂肪变性及轻微的炎性浸润,程度轻于模型组。易善复组肝组织炎性改变程度与脂易消组比较没有明显的差异。结论:脂易消能改善肝细胞脂肪性变及肝组织炎性病变,提高肝组织 ChREBP m RNA 表达水平,对高脂饮食引起的 NAFLD 有治疗作用,具有与易善复相似的疗效。
Objective:To observe the influence of Zhiyixiao on experimental nonalcoholic fatty liver disease (NAFLD) rat liver tissue carbohydrate response element binding protein (ChREBP) on the expression of mRNA.Method:Given high fat diet to NAFLD rat model, divided them into low, medium, high Zhiyixiao treated group, Yishanfu capsule in the positive control group, saline control group, normal control group.Microscopically observed by HE staining in all groups after fatty degeneration of liver cells and the liver tissue inflammatory changes;the use of RT-PCR was detected by rat liver tissue ChREBP levels of mRNA.Result:At the end of the experiment in model group, body mass index (BMI) were significantly increased, compared with the normal group the differences were statistically significant (P〈0.01);and compared with the model group, the index of all Zhiyixiao groups and Yishanfu group decreased significantly (P〈0.05);but the high, medium, low treated groups and Yishanfu group there were no significant differences(P〉0.05).The light microscope showed that the normal group had no fatty degeneration and inflammatory infiltration;group model overall liver fatty degeneration degree compared with that in normal liver tissues had significant difference.Conclusion:Zhiylxiao can improve liver steatosis and liver tissue inflammatory diseases, improve liver tissue ChREBP expression level of mRNA, on high fat diet induced by NAFLD treatment, and Yishanfu has similar efficacy.
出处
《中国医学创新》
CAS
2012年第22期1-4,共4页
Medical Innovation of China
基金
浙江省科技厅资助课题(编号:2009C33161)